OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
In recognition of Metastatic Breast Cancer Awareness Day on October 13, AstraZeneca (NYSE: AZN) is raising awareness about the thousands of U.S. women living with metastatic breast cancer. Metastatic Breast Cancer Awareness Day seeks to generate attention and greater support for women living with metastatic breast cancer among the public and stakeholders within the breast cancer community and more research to extend lives.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58129-mbc-awareness
In the lead-up to Lung Cancer Awareness Month this November, the ‘future face’ of women’s cancer is being revealed. While new data published last month by Cancer Research UK suggests the number of women dying from breast cancer in the UK is in decline – expected to drop almost 30 percent by 2030 – the number of women dying from lung cancer is on the increase.
Liz Darlison, Macmillan Consultant Nurse Specialist, University Hospitals of Leicester, says, “While the statistics paint a frightening picture, there’s a great deal that can be done to help ensure women are diagnosed earlier, treated earlier and live longer. By raising awareness of the tell-tale signs – for example, a persistent cough that lasts longer than three weeks – there’s the potential to save thousands of lives every year.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56634-lilly-uk-lung-cancer-awareness
To help combat an increasing trend in festive isolation, charity Abbeyfield today launches a nationwide campaign, Companionship At Christmas, to create an alternative to spending the celebratory period alone. The charity is offering free overnight stays and delicious Christmas lunches over the festive season (24th December – 4th January) in over 100 Abbeyfield sheltered houses and care homes. The Charity will take enquiries from now until December via their website or via their dedicated telephone number 0845 052 3553 up until the 18th December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58633-abbeyfield-launches-companionship-at-christmas-campaign
Research led by the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.
The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia
Golden Globe and Emmy nominated actress Elizabeth Perkins, who is living with type 1 diabetes, is partnering with Sanofi US on the Diabetes Co-Stars awareness campaign to produce a new documentary that will feature people living with diabetes and those who support them. Beginning today through December 16, 2012, people can submit their stories to the nationwide casting call at www.DiabetesCoStars.com.
To view Multimedia News Release, go to https://www.multivu.com/mnr/57457-sanofi-us-elizabeth-perkins-casting-call-diabetes-co-stars-documentary
Approximately 1.5 million women and girls in the United States have epilepsy, of which nearly 500,000 are women of childbearing age. Treating women with epilepsy, especially women of childbearing age, presents significant challenges to physicians. Epilog.us [http://www.epilog.us], Upsher-Smith Laboratories, Inc’s [http://www.upsher-smith.com] epilepsy-focused educational website, discusses these challenges and provides professional insight by some of the epilepsy community’s most respected physicians including Dr. Cynthia Harden, Chief of the Comprehensive Epilepsy Care Center, North Shore University Hospital and Long Island Jewish Medical Center, and Dr. Christopher Skidmore, Director of Neurology Residency/Assistant Professor of Neurology, at Jefferson Medical College of Thomas Jefferson University.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59306-upsher-smith-epilog-website-challenges-in-managing-women-with-epilepsy
Anytime Fitness, the world’s largest and fastest-growing co-ed fitness club chain, announced today the opening of its 2,000th club in The Netherlands. Founded in 2002, it took Anytime Fitness only 10 years to reach the 2,000-unit mark, less than half as long as other well-known franchises like Subway (23 years) and McDonald’s (32 years).
“Some businesses focus on quick growth and others specialize in earning customer loyalty,” said Chuck Runyon, Anytime Fitness CEO and co-founder. “We take great pride in having achieved both of those accomplishments simultaneously. We’ve done so by focusing first on the needs of busy people who simply want to lead a healthier lifestyle and then by providing our franchisees with the practical tools, technology and educational support to help members achieve their goals.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56352-anytime-fitness-opens-its-2000th-club-in-10-years
A child’s inspirational artwork for a holiday card will drive awareness, donations and hope in the fight against childhood cancer as the centerpiece of a new digital holiday campaign launching today by Northwestern Mutual. The campaign, Share Unstoppable Happiness!, aims to raise up to $25,000 by Dec. 30 for Northwestern Mutual’s Childhood Cancer Program nonprofit partners, Alex’s Lemonade Stand Foundation and Starlight Children’s Foundation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53665-northwestern-mutual-digital-holiday-campaign-to-fight-childhood-cancer
With the Dec. 7 deadline for Medicare’s annual enrollment period fast approaching, Smart Insurance Company is working with Walgreens to offer in–store consultations with licensed SmartD Rx plan agents, available at select Walgreens to speak with Medicare beneficiaries who are either enrolling in a new Part D prescription drug plan or evaluating their current coverage options.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59273-smart-insurance-company-walgreens-smartd-rx-open-enrollment-ends-dec-7
Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine today, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59399-phoenix-children-s-hospital-visionary-institute-of-molecular-medicine
